Jeffrey Beauregard
Neurology · Holland, MINPI 1710480967
Payments from drug & device makers
Across 113 payments — averaging $183.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$15K
- Pfizer$4K
- Kyowa Kirin, Inc.$122
- Biohaven Pharmaceuticals, Inc.$122
- Adamas Pharmaceuticals, Inc.$120
- Sanofi$120
- plus $674 from 12 others
What the payments were for
- Speaking & faculty fees$18,37889%
- Food & beverage$2,30611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 90 | $15,261 |
| Pfizer | 3 | $4,265 |
| Kyowa Kirin, Inc. | 1 | $122 |
| Biohaven Pharmaceuticals, Inc. | 1 | $122 |
| Adamas Pharmaceuticals, Inc. | 1 | $120 |
| Sanofi | 2 | $120 |
| AstraZeneca | 1 | $118 |
| SK Life Science, Inc. | 2 | $105 |
| E.r. Squibb & Sons, L.L.C. | 1 | $92 |
| Teva Pharmaceuticals USA, Inc. | 1 | $82 |
| TG Therapeutics, Inc. | 1 | $81 |
| Neurelis, Inc. | 1 | $54 |
| Eisai Inc. | 2 | $32 |
| Biogen | 2 | $30 |
| Livanova USA, Inc. | 1 | $26 |
| Argenx US, Inc. | 1 | $26 |
| Acorda Therapeutics, Inc | 1 | $15 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$11,900
- UBRELVY$8,500
- NURTEC ODT$4,358
- NOURIANZ$122
- GOCOVRI$120
How this compares
$20,684 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 17 | $19,074 |
| Dalfampridine ErDalfampridine | 18 | $9,190 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 104 | $5,632 |
| Propranolol Hcl ErPropranolol Hcl | 91 | $4,912 |
| Lacosamide | 33 | $3,876 |
| Donepezil Hcl | 194 | $2,828 |
| Pregabalin | 62 | $2,531 |
| Levetiracetam | 55 | $2,298 |
| Memantine Hcl | 93 | $1,789 |
| Gabapentin | 117 | $1,630 |
| Oxcarbazepine | 22 | $1,293 |
| Sertraline Hcl | 106 | $1,132 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 25 | $906 |
| Primidone | 12 | $774 |
| Duloxetine Hcl | 46 | $748 |
Paid to pharmacies, not to this prescriber.
Other neurology in Holland
- Aaron EllenbogenFarmington Hills$14.5M
- Martin BelkinFarmington Hills$5.8M
- Evanthia BernitsasDetroit$4.8M
- Yang Mao DraayerFarmington Hills$4.2M
- Mirela CerghetDetroit$3.8M
- Peter le WittWest Bloomfield$3.2M
- Judith HeidebrinkAnn Arbor$2.2M
- Denise LeungAnn Arbor$2M
- Rany AburashedOwosso$1.9M
- Jeanie CoteOwosso$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.